Magnesium Carbonate

MONDAY, Dec. 23, 2024 -- Coffee provides a quick morning boost, but it might also protect the brain health of people with a common heart rhythm disorder . A study published recently in the Journal of the American Heart Association shows patients with atrial fibrillation who drank more than five cups of coffee a day performed better on an array of cognitive tests than those who drank little to no coffee. In fact, the brains of heavy coffee drinkers were nearly seven years younger in cognitive age compared to coffee teetotalers. “Many myths are around, but our study found no reason to discourage or forbid a patient with A-Fib from drinking coffee. Instead, say, ‘Enjoy, it may even be good for you!’” senior researcher Dr. Jürg Beer , a professor of medicine and hematology at the University of Zürich in Switzerland, said in an American Heart Association (AHA) news release. Atrial fibrillation is the most common heart rhythm disorder in adults, affecting more than 5 million people in the United States, according to the AHA. A-Fib occurs when the upper chambers of the heart -- the atria -- begin beating in a quivering and uncoordinated way. This allows blood to pool in the atria and potentially clot. A-Fib increases a person’s risk of stroke fivefold, as a blood clot can travel from the atria and block blood flow to the brain, according to the U.S. Centers for Disease Control and Prevention. Current American Heart Association guidelines say that abstaining from caffeine doesn’t benefit people with A-Fib, unless patients report that caffeine triggers or worsens their symptoms, researchers noted. Symptoms can include rapid heartbeat, dizziness, fatigue, shortness of breath and chest pain. “It is known that regular coffee consumption benefits cognitive performance among healthy people. The most frequent cardiac arrhythmia, atrial fibrillation, is known to independently increase the risk of dementia,” said lead researcher Dr. Massimo Barbagallo , a resident in the neuro intensive care unit at the University Hospital Zürich. “Thus, the question is whether coffee might offset the increased risk of cognitive impairment in people with A-Fib,” Barbagallo said. For the study, researchers recruited more than 2,400 people in Switzerland diagnosed with atrial fibrillation between 2014 and 2017. Participants completed several brain tests and reported how many cups of caffeinated coffee they drank during the last 12 months. Results showed that the more coffee a person drank, the better they performed on cognitive tests. “There was a very clear and consistent ‘dose-response’ association between drinking more coffee and doing better on several different sophisticated cognitive tests,” Beer said. Specifically, their scores were about 11% higher than people who drank little to no coffee, researchers found. Coffee also appeared to lower inflammation in A-Fib patients. Inflammatory markers were more than 20% lower in people drinking five cups daily than those drinking less than one cup a day. “Inflammatory markers decreased with higher coffee consumption, an association that remained after considering variables such as age, sex, body mass index, smoking status, physical activity and a history of stroke,” Beer said. It’s not quite clear why coffee might help brain health, researchers said. It could be due to caffeine or other active ingredients in coffee, like magnesium and niacin, or it might be due to coffee’s anti-inflammatory effects. However, an outside expert warns that this observational study cannot prove a direct link between heavy coffee drinking and better brain aging, particularly in people with A-Fib. “Other studies have shown coffee has cognitive-enhancing functions across the board. This, however, is not specific to the A-Fib population. We cannot conclude that coffee prevents long-term cognitive decline,” said Dr. Jose Joglar , a professor of internal medicine at UT Southwestern Medical Center in Dallas. “Coffee does not seem to worsen A-Fib so there is no need to stop drinking it,” Joglar continued. “However, we cannot say starting to drink coffee would prevent A-Fib or prevent long-term cognitive decline.” Researchers also noted that the study measured brain health and coffee consumption at the same point in time, so it could not track the long-term effect of coffee on brain aging over time. “To detect a relevant cognitive decline, a follow-up of at least 5 to 10 years is required,” Barbagallo said. “However, the nutritive habits including coffee consumption reported by participants reflect exposure over many years and we likely see here the results of this.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

HERZLIYA, Israel and CALGARY, AB, Feb. 13, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company" or " Innocan"), is pleased to provide the following corporate update: Innocan is uniquely positioned within the pharmaceutical technology industry with its dual focus on pharmaceuticals and consumer wellness, leveraging cutting-edge science to enhance patient and consumer well-being. Technological Edge: Innocan's product development is centered around its proprietary CBD-loaded liposome platform technology ("LPT"), a testament to its commitment to innovation. This technology is designed for both human and animal applications, offering a new paradigm in treatment efficacy and safety. Additionally, Innocan's consumer wellness portfolio, featuring topicals and cosmetics, underscores its dedication to health and wellness, catering to the growing consumer demand for effective wellness products. The Opportunity: The global pain management market presents a vast opportunity for Innocan. With over 20% of adults in the US market reporting chronic pain,[1] the need for novel and effective treatments is more pressing than ever. As Innocan enters the market, Innocan's innovative technology and focus on CBD's therapeutic potential positions it well in this sizeable and growing marketplace. Product Overview Innocan's product portfolio includes advanced CBD-based formulations for both injectable and topical applications. The product portfolio includes patent-pending, injectable liposome-delivery platforms for human and veterinary use, and a range of topical products for direct pain relief and wellness product lines. Each product category is at a strategic development and growth stage backed by clinical & efficacy trials. Market Summary The pain management market for human applications continues to grow, targeting US$109 billion by 2032.[2] Similarly, the market for topical pain relief is forecasted to grow significantly, from US$10.68 billion in 2023 to over US$14 billion by 2028.[3] For animal applications, the global veterinary medicine market is expected to reach nearly US$50 billion by 2024, with the pain management segment experiencing robust growth.[4] Regulatory Pathway "The development of our LPT platform is progressing much faster than is usual in the pharmaceutical sector," said Prof. Chezy Barenholz, Innocan's scientific director. Innocan has been able to obtain extensive data derived from several pre-clinical studies previously conducted on various animal models including mice, dogs, and goats. The data obtained from these studies indicated a similar behavior of the drug among the different animals exhibited by long pharmacokinetics over weeks, high bioavailability, good drug tolerance and long-lasting efficacy. Studies conducted in large mammals supported LPT-CBD efficacy by showing long lasting relieving effect in indications such as chronic pain and drug resistance epileptic seizures. Innocan is currently testing the LPT platform on a new animal species and expects to receive results shortly. Following successful pre-clinical trials, Innocan is actively pursuing United States Food and Drug Administration (" FDA") approval for our human pharmaceutical applications. Innocan expects that pre-investigational new drug applications will be submitted to the FDA before the end of March, 2024. Innocan boasts a robust intellectual property portfolio, comprising 12 families of patent applications. These applications include a diverse range of conditions, including pain management, diabetes and vaginal applications. One patent family has already been granted in the United States related to the Company's combined cannabis and magnesium topical pain-relief technology. Preliminary Q4 and Fiscal Year 2023 Financial Highlights (unaudited) Innocan's preliminary revenues for Q4 2023 are expected to be at least US$4.89M, representing an approximate increase of 20% from Q3 2023 and an increase of at least 331% compared to Q4 2022. For the 2023 fiscal year, Innocan's preliminary revenues are expected to be at least US$13.6 million, representing an approximate increase of 433% over fiscal year 2022. This surge in revenue is primarily attributable to the robust sales performance of Innocan's subsidiary, B.I. Sky Global Ltd. These preliminary revenue figures exceed expenses in the respective periods. The above information should be read in conjunction with Innocan's audited consolidated financial statements as of December 31, 2023 (the " Audited Financial Statements"), and the accompanying management's discussion and analysis for the year ended December 31, 2023, which will be filed on the Innocan's SEDAR+ profile at . Corporate Update Link About Innocan Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. For further information, please contact: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer Regarding Financial Information The financial information presented in this press release is based on preliminary, unaudited financial statements prepared by management, for the fourth quarter and fiscal year ended December 31, 2023. Accordingly, such financial information may be subject to change. While the Company does not expect there to be any material changes to the financial information presented in this press release, to the extent that it is inconsistent with the information contained in the Audited Financial Statements, the financial information contained in this news release shall be deemed to be modified or superseded by such Audited Financial Statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Caution regarding forward-looking information Certain information set forth in this news release, including, without limitation, the Company's positioning in the global pain management market, expectations regarding the size of the human and veterinary pain management markets, growth potential for the Company's products as they are introduced to the market, plans for strategic expansion in the human pharmaceuticals, veterinary and topical market segments, statements relating to the Company's financial results for Q4 2023 and the 2023 fiscal year, expectations regarding the timing for submission of the Company's pre-investigational new drug applications to the FDA, and expectations regarding the Company's pending patent applications, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. [1] One in Five U.S. Adults Have Chronic Pain — Pain News Network, Study finds high rates of persistent chronic pain among US adults (medicalxpress.com); Pain Management Therapeutics Market Size Report 2022 to 2030 (precedenceresearch.com) [2] Pain Management Drugs Market Share, Trends & Forecast, 2032 (gminsights.com) [3]Study finds high rates of persistent chronic pain among US adults (medicalxpress.com), [4] Veterinary Medicine Market - Trends, Growth & Size (mordorintelligence.com) Logo: SOURCE Innocan Pharma Corporation